Braxia Scientific Announces Voting Results from the Annual General Meeting of Shareholders
TORONTO, ONTARIO October 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the voting results from its Annual General Meeting of Shareholders held on Thursday, October 28, 2021. A total of 11.77% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting.
The following 4 nominees proposed by the Company were elected as Directors of Braxia Scientific to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
| Director | For | % | Withheld | % |
| Roger McIntyre | 19,070,776 | 96.13 | 742,771 | 3.74 |
| Jerry Habuda | 16,845,734 | 84.91 | 2,992,813 | 15.09 |
| Olga Cwiek | 17,210,282 | 86.75 | 2,628,265 | 13.25 |
| David Greenberg | 17,238,532 | 86.89 | 2,575,015 | 12.98 |
In addition to the election of all nominees listed as directors in the management information circular, dated September 16, 2021, Braxia’s shareholders approved all other resolutions placed before the meeting. These included appointing DMCL as auditors for the Company for the ensuing year.
For more details on the matters covered at the annual meeting, please refer to the Company’s management information circular available on SEDAR at www.sedar.com.
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO
FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website: www.braxiascientific.com